Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 20.07.2026 1 Am J Surg 14 Ann Surg Oncol 7 BMC Cancer 3 Br J Cancer 4 Breast Cancer 3 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 6 Breast Cancer Res Treat 2 Breast J 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Lett 7 Clin Breast Cancer 3 Clin Cancer Res 6 Eur J Surg Oncol 1 Histopathology 1 Int J Cancer 4 Int J Radiat Oncol Biol Phys 1 J Biol Chem 2 J Clin Invest 2 J Clin Oncol 1 J Natl Cancer Inst 2 J Surg Oncol 1 JAMA 2 Lancet Oncol 1 NPJ Breast Cancer 1 Oncogene 1 Oncol Rep 3 PLoS One 2 Proc Natl Acad Sci U S A 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. LIU C, Warburton R, Deban M, Newman-Bremang J, et al
   The hidden costs of choice: Increased postoperative risks in patient-preference mastectomy for breast cancer.
   Am J Surg. 2026;260:117139.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ZAVERI S, Whitham ZA, Nguyen A, Nadar A, et al
   Variation in Surgical Management of Stage IV Breast Cancer: Local/Institutional and Regional Geographic Considerations.
   Ann Surg Oncol. 2026 Jul 11. doi: 10.1245/s10434-026-20123.
   PubMed         Abstract available
   
   
3. BOYLE MK, Giuliano AE
   ASO Author Reflections: Evolving Axillary Management in Young Women with Breast Cancer.
   Ann Surg Oncol. 2026 Jul 13. doi: 10.1245/s10434-026-20059.
   PubMed        
   
   
4. VARMAN PM, Taft DA, Patel M, Rangan R, et al
   ASO Visual Abstract: Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?
   Ann Surg Oncol. 2026 Jul 14. doi: 10.1245/s10434-026-20174.
   PubMed        
   
   
5. VARMAN PM, Rangan R, Maggiotto A, Wu V, et al
   Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction.
   Ann Surg Oncol. 2026 Jul 14. doi: 10.1245/s10434-026-20143.
   PubMed         Abstract available
   
   
6. JAEN DM, Dougherty CE, Helseth KA, Harwell PA, et al
   ASO Visual Abstract: Nodal Pathologic Response after Neoadjuvant Systemic Therapy in Clinically Advanced Node-Positive (cN2 and cN3) Breast Cancer.
   Ann Surg Oncol. 2026 Jul 14. doi: 10.1245/s10434-026-20204.
   PubMed        
   
   
7. VARMAN PM, Rangan R, Maggiotto A, Wu V, et al
   ASO Visual Abstract: Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction.
   Ann Surg Oncol. 2026 Jul 15. doi: 10.1245/s10434-026-20211.
   PubMed        
   
   
8. VARMAN PM, Taft DA, Patel M, Rangan R, et al
   Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?
   Ann Surg Oncol. 2026 Jul 16. doi: 10.1245/s10434-026-20128.
   PubMed         Abstract available
   
   
9. MEHTA D, Robinson D, Komenaka M, Welch J, et al
   Implementation of Green Changes Can Result in Shortened Turnover and Decreased Surgical Waste in Breast Cancer Operations.
   Ann Surg Oncol. 2026 Jul 16. doi: 10.1245/s10434-026-20140.
   PubMed         Abstract available
   
   
10. ZHANG L, Birla S, Tang SX, Galloway OW, et al
    ASO Visual Abstract: Impact of Total and Positive Lymph Node Count on Recurrence in Young Women with Node-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2026 Jul 16. doi: 10.1245/s10434-026-20222.
    PubMed        
    
    
11. CHEN JH, Peregrin-Alvarez I, Warneke CL, McKenzie LJ, et al
    ASO Visual Abstract: Oncologic Safety of Preoperative Controlled Ovarian Stimulation for Fertility Preservation Among Women with Estrogen Receptor-Positive Breast Cancer.
    Ann Surg Oncol. 2026 Jul 16. doi: 10.1245/s10434-026-20221.
    PubMed        
    
    
12. KOPKASH K, Piltin M, Jakub J, Javid S, et al
    A Prospective, Multicenter Randomized Controlled Trial (RCT) of the da Vinci SP((R)) Surgical System versus Open Surgery in Nipple-Sparing Mastectomy (NSM) Procedures for Patients with Breast Cancer.
    Ann Surg Oncol. 2026 Jul 16. doi: 10.1245/s10434-026-20201.
    PubMed         Abstract available
    
    
13. PRATHIBHA S, Day CN, Black DM, Boughey JC, et al
    Evolution of Axillary Surgical Management of Patients with Occult Breast Cancer with Axillary Metastasis.
    Ann Surg Oncol. 2026 Jul 17. doi: 10.1245/s10434-026-20155.
    PubMed         Abstract available
    
    
14. TSENG J, Boughey JC, Mukhtar RA
    ASO Author Reflections: Young Women with Breast Cancer may Safely Opt for Breast Conservation After Neoadjuvant Therapy.
    Ann Surg Oncol. 2026 Jul 17. doi: 10.1245/s10434-026-20250.
    PubMed        
    
    
15. MOKHBER A, Tang K, Situ O, O'Neill AC, et al
    Association Between Decision Regret and Psychosocial Outcomes Following Surgery Among Women with Unilateral Nonhereditary Breast Cancer.
    Ann Surg Oncol. 2026 Jul 17. doi: 10.1245/s10434-026-20124.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. FERNANDEZ JK, Harris G, Leow BYJ, Beith J, et al
    Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16495.
    PubMed         Abstract available
    
    
17. SEZAVAR AH, Fakhari F, Jafarzadeh E, Montazeri V, et al
    Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16544.
    PubMed         Abstract available
    
    
18. SHEN K, Cai L, Wu W
    Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation.
    BMC Cancer. 2026 Jul 15. doi: 10.1186/s12885-026-16530.
    PubMed         Abstract available
    
    
19. NGUYEN HT, Vu MD, Nguyen DD, Dinh PN, et al
    Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
    BMC Cancer. 2026;26:858.
    PubMed         Abstract available
    
    
20. FUJIMOTO A, Ichinose Y, Matsuura K, Mikami E, et al
    Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16548.
    PubMed         Abstract available
    
    
21. ALABI A, Boateng F, Swanson W, Sowunmi A, et al
    Radiation therapy in breast cancer patients in south west Nigeria: an evaluation of protocols in a specialist cancer centre.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16483.
    PubMed         Abstract available
    
    
22. KIRACI M, Soyturk G, Kos FT, Perkin P, et al
    Nailfold capillaroscopy findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction.
    BMC Cancer. 2026;26:855.
    PubMed         Abstract available
    
    

    
    Br J Cancer

23. JORGENSEN KJ, Brodersen JB
    Risk-based breast cancer screening.
    Br J Cancer. 2026 Jul 17. doi: 10.1038/s41416-026-03557.
    PubMed        
    
    
24. ALIU AE, Kerrison RS, Marcu A
    Black women's decisions about participating in breast cancer screening in the UK: a qualitative study.
    Br J Cancer. 2026 Jul 16. doi: 10.1038/s41416-026-03551.
    PubMed         Abstract available
    
    
25. HILL H, Roadevin C
    Economic evaluation of artificial intelligence for cancer detection in the UK breast screening programme.
    Br J Cancer. 2026;135:453-460.
    PubMed         Abstract available
    
    

    
    Breast Cancer

26. GEORGE PS, Mathew A, Kaur T, Dhaliwal RS, et al
    Risk factors associated with molecular subtypes of breast cancer among indian women: a multicentre matched case-control study.
    Breast Cancer. 2026 Jul 13. doi: 10.1007/s12282-026-01891.
    PubMed         Abstract available
    
    
27. HOSHINO A, Ohi Y, Yamaguchi R, Tsuda H, et al
    Interobserver reproducibility of macroscopic classification of breast cancer from representative cut surface of resected specimens and hematoxylin-eosin-stained slides.
    Breast Cancer. 2026 Jul 11. doi: 10.1007/s12282-026-01888.
    PubMed         Abstract available
    
    
28. MASUDA H, Konishi T, Onishi M, Ito A, et al
    Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.
    Breast Cancer. 2026 Jul 17. doi: 10.1007/s12282-026-01887.
    PubMed         Abstract available
    
    
29. YAO Y, Zhai X, Liang Z, Lam CK, et al
    Interpretable machine-learning survival prediction of breast cancer prognosis from lifestyle factors: evidence from UK biobank.
    Breast Cancer. 2026 Jul 17. doi: 10.1007/s12282-026-01893.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

30. CHEN J, Zhao Z, Xing Y, Li X, et al
    AIM2 Lactylation Regulates Radiotherapy Sensitivity in Triple-Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:613159.
    PubMed         Abstract available
    
    
31. AYDIN F, Yuksel C, Akyuz C, Pulat H, et al
    HER2 Expression and Axillary Metastasis in Treatment-Naive Early Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:618927.
    PubMed         Abstract available
    
    
32. AL-SARAIREH YM, Alshammari FOFO, Hassan HA, Jaradat JH, et al
    CYP4B1 Expression in Breast Cancer: An Immunohistochemical Study with Complementary in silico Analyses.
    Breast Cancer (Dove Med Press). 2026;18:612743.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

33. LU H, Bagheri M, Kolling FW, Salas LA, et al
    Epithelial-mesenchymal transition is associated with altered immune composition and cytotoxic function in triple-negative breast cancer.
    Breast Cancer Res. 2026;28:132.
    PubMed         Abstract available
    
    
34. COSENTINO G, Lecchi M, Giussani M, Fogazzi V, et al
    Three ct-miRNA signature predicts disease outcome in early breast cancer women.
    Breast Cancer Res. 2026 Jul 15. doi: 10.1186/s13058-026-02344.
    PubMed         Abstract available
    
    
35. CAO A, Fuller S, Zanudo JGT, Chen WY, et al
    Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.
    Breast Cancer Res. 2026 Jul 10. doi: 10.1186/s13058-026-02337.
    PubMed         Abstract available
    
    
36. LONG J, Liu B, Li J, Wang X, et al
    Development and validation of an immune-related molecular subtyping model based on a four-gene prognostic biomarker signature and multi-omics integrative analysis in Luminal B breast cancer.
    Breast Cancer Res. 2026 Jul 10. doi: 10.1186/s13058-026-02342.
    PubMed         Abstract available
    
    
37. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea Baz N, Pachon-Olmos V, et al
    Adherence to the WCRF/AICR cancer prevention recommendations and mammographic density.
    Breast Cancer Res. 2026;28:131.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

38. LIU C, Warburton R, Pao JS, Dingee CK, et al
    Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery.
    Breast Cancer Res Treat. 2026;218:11.
    PubMed         Abstract available
    
    
39. FOO CY, Sehrawat O, Puri A, Haque W, et al
    Clinicopathologic features, treatment patterns and survival outcomes of acinic cell carcinoma of the breast: a national cancer database analysis.
    Breast Cancer Res Treat. 2026;218:13.
    PubMed         Abstract available
    
    
40. TERAN S, Illia M, Quevedo MC, Moreno ML, et al
    Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.
    Breast Cancer Res Treat. 2026;218:12.
    PubMed         Abstract available
    
    
41. GOH SSN, Zhou X, Ng QX, Kulkarni D, et al
    Extended applications of chest wall perforator flaps in breast surgery: case series and systematic literature review.
    Breast Cancer Res Treat. 2026;218:14.
    PubMed         Abstract available
    
    
42. BYEMERWA J, Neish D, Forgah L, Deveaux A, et al
    Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study.
    Breast Cancer Res Treat. 2026;218:10.
    PubMed         Abstract available
    
    
43. AMRITT A, Dagar A, Ghosh A, Maiti A, et al
    Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer.
    Breast Cancer Res Treat. 2026;218:9.
    PubMed         Abstract available
    
    

    
    Breast J

44. SHAYEGHAN M, Shahriari F, Afroughi F, Forouzesh F, et al
    Pivotal Factors in Breast Cancer Molecular Subtypes Apoptosis Induction by ELF-EMF; Ki-67, ROS Level, HER-2, and SODs.
    Breast J. 2026;2026:e9572421.
    PubMed         Abstract available
    
    
45. KHADROUCHE T, Morisseau M, Selmes G, Vaysse C, et al
    Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple-Negative Breast Cancer.
    Breast J. 2026;2026:e5534220.
    PubMed         Abstract available
    
    

    
    Cancer

46. BAEKER BISPO J, Lee H, Tian J, Jemal A, et al
    Civic engagement and breast cancer screening participation among US citizens.
    Cancer. 2026;132:e70468.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

47. SCONTRE VA, Toyoshima MTK, Estevez-Diz MDP
    Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life.
    Cancer Chemother Pharmacol. 2026;96:75.
    PubMed         Abstract available
    
    

    
    Cancer Lett

48. YU Y, Liu L, Cai Y, Wang T, et al
    Membrane bionic supramolecular nanomaterials for co-delivered of ribociclib and PEG10 siRNA for targeted therapy in breast cancer.
    Cancer Lett. 2026 Jul 15:218737. doi: 10.1016/j.canlet.2026.218737.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

49. ELAYOUBI J, Tang C, Ruddy KJ, Choucair K, et al
    Refining Stratification in Premenopausal Node-Positive HR(+)/HER2(-) Breast Cancer With a Novel AI-Based Test.
    Clin Breast Cancer. 2026;26:14-20.
    PubMed         Abstract available
    
    
50. GU Z, Zhang Y, Ye Y, Qian W, et al
    Axillary Management After Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer.
    Clin Breast Cancer. 2026;26:72-79.
    PubMed         Abstract available
    
    
51. MODI S, Murthy RK, Chien AJ, Lin NU, et al
    Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.
    Clin Breast Cancer. 2026;26:21-30.
    PubMed         Abstract available
    
    
52. YANG C, Tang L, Zhang L, Karam I, et al
    Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis i
    Clin Breast Cancer. 2026;26:31-38.
    PubMed         Abstract available
    
    
53. TAGHIAN AJ, Aggarwal M, Shui AM, Stolker S, et al
    Health-Related Quality of Life in Early Breast Cancer Treatment and Effects of Surgery Type and Body Mass Index.
    Clin Breast Cancer. 2026;26:65-71.
    PubMed         Abstract available
    
    
54. BERNER-WYGODA Y, Alibhai SM, Savill J, Kimmel A, et al
    Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort.
    Clin Breast Cancer. 2026;26:57-64.
    PubMed         Abstract available
    
    
55. LIU J, Tang M, Jia F, Wang Z, et al
    Habitat-Based MRI Radiomics for Predicting Breast-Conserving Surgery Feasibility After Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter Study.
    Clin Breast Cancer. 2026;26:39-48.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

56. WAKS AG, Segui E, Li T, Lipsyc-Sharf M, et al
    Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.
    Clin Cancer Res. 2026 Jul 13. doi: 10.1158/1078-0432.CCR-26-0721.
    PubMed         Abstract available
    
    
57. DIECI MV, Gasparini E, Nicole L, Schmid P, et al
    Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.
    Clin Cancer Res. 2026 Jul 17. doi: 10.1158/1078-0432.CCR-26-0975.
    PubMed         Abstract available
    
    
58. DONG W, Wang S, Chan B, Vasquez M, et al
    Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer.
    Clin Cancer Res. 2026 Jul 17. doi: 10.1158/1078-0432.CCR-25-4894.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

59. KANG J, Lee S, Jung S, Yoon Y, et al
    Prognostic impact of close margins on Loco-regional recurrence in ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy.
    Eur J Surg Oncol. 2026;52:111906.
    PubMed         Abstract available
    
    
60. ESGUEVA A, Pitoni L, Regueira F, Rodriguez-Spiteri N, et al
    Optimizing breast conservative surgery for ductal carcinoma in situ: Comparative outcomes of intraoperative ultrasound and wire localization in achieving negative margins.
    Eur J Surg Oncol. 2026;52:111919.
    PubMed         Abstract available
    
    
61. GUI G, Rusby JE, Tasoulis MK
    An algorithmic approach to implant based immediate breast reconstruction.
    Eur J Surg Oncol. 2026;52:111941.
    PubMed         Abstract available
    
    
62. CATANUTO GF, D'Amico S, Gentile D, Bruseghini A, et al
    Synthetic data generation from population-based breast cancer registries: opportunities and limitations for survival analysis applications.
    Eur J Surg Oncol. 2026;52:111996.
    PubMed         Abstract available
    
    
63. MUNCK F, Gartner R, Palshof FK, Tvedskov THF, et al
    Patient-reported pain after targeted axillary dissection for breast cancer.
    Eur J Surg Oncol. 2026;52:111994.
    PubMed         Abstract available
    
    
64. GODINO L, Innella G, Di Palo C, Bono GR, et al
    Uptake of breast cancer risk-management strategies among unaffected BRCA 1/2 carriers: a systematic review of international evidence.
    Eur J Surg Oncol. 2026;52:111991.
    PubMed         Abstract available
    
    

    
    Histopathology

65. SHAABAN AM, Dodson A, Rakha E, Ellis I, et al
    UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.
    Histopathology. 2026 Jul 18. doi: 10.1111/his.70235.
    PubMed         Abstract available
    
    

    
    Int J Cancer

66. GRAESER M, Bothin S, Gluz O, Warm M, et al
    Value of Axillary Palpation and Ultrasound, and Axillary Recurrence in Male Breast Cancer: Results of the Registry Study.
    Int J Cancer. 2026 Jul 16. doi: 10.1002/ijc.70658.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

67. NAOUM GE, Taghian A, Kaidar-Person O, Meattini I, et al
    Integration of Breast Reconstruction and Radiation: How the Proton-Photon Debate Exposes Methodological Gaps, Analytical Bias, and Lack of Consensus.
    Int J Radiat Oncol Biol Phys. 2026;125:1368-1380.
    PubMed         Abstract available
    
    
68. IYER P, Krishnamurthy A, Velusamy S, Sundersingh S, et al
    Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Locally Advanced Inoperable Breast Cancer- A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY).
    Int J Radiat Oncol Biol Phys. 2026 Jul 10:S0360-3016(26)03949.
    PubMed         Abstract available
    
    
69. PALUMBO I, Becchetti AG, D'Angelo E, De Santis MC, et al
    Ultra-hypofractionated whole breast irradiation in early-stage breast cancer: an Italian multi-centre observational study.
    Int J Radiat Oncol Biol Phys. 2026 Jul 15:S0360-3016(26)03996.
    PubMed         Abstract available
    
    
70. NEIBART SS, Taylor M, Depauw N, Yeap BY, et al
    Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:1338-1347.
    PubMed         Abstract available
    
    

    
    J Biol Chem

71. PIMENTEL JM, Bosompra O, Trejo J
    The deubiquitinase CYLD inhibits thrombin-induced p38 MAPK-p65 NF-kappaB signaling and inflammatory cytokine production to suppress triple-negative breast cancer progression.
    J Biol Chem. 2026 Jul 16:113341. doi: 10.1016/j.jbc.2026.113341.
    PubMed         Abstract available
    
    

    
    J Clin Invest

72. ARABZADEH M, Tang YH, Colin-Leitzinger C, Marzban S, et al
    Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.
    J Clin Invest. 2026;136:e204429.
    PubMed         Abstract available
    
    
73. RUIZ-SEPULVEDA JL, Bueno MJ, Mouron S, Jimenez-Renard V, et al
    Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models.
    J Clin Invest. 2026;136:e174092.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

74. NAHLEH Z, Alfano CM, Somerfield MR, Lee JM, et al
    Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.
    J Clin Oncol. 2026 Jul 16:101200JCO2601700. doi: 10.1200/JCO-26-01700.
    PubMed         Abstract available
    
    
75. LIPSYC-SHARF M, Hurvitz SA
    Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.
    J Clin Oncol. 2026 Jul 13:JCO2600672. doi: 10.1200/JCO-26-00672.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

76. TARANTINO P, Curigliano G, Hamilton E, Kim J, et al
    Recurrence risk in HR-positive/HER2-negative early breast cancer: real-world US electronic health records study.
    J Natl Cancer Inst. 2026 Jul 11:djag201. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

77. KIM M, Bubberman JM, Wang J, Boe LA, et al
    The Impact of Time and Place on BREAST-Q REACT: A Multi-Institutional Examination.
    J Surg Oncol. 2026;134:31-40.
    PubMed         Abstract available
    
    
78. GIVANT M, Friedman R, Fanning JE, Chen A, et al
    Superficial and Functional Imaging of the Posterior Upper Arm Pathway in the Healthy Population.
    J Surg Oncol. 2026;134:128-134.
    PubMed         Abstract available
    
    

    
    JAMA

79. RUBIN R
    Breast Cancer Recommendations Fuel Debate Over Who Should Write Screening Guidelines.
    JAMA. 2026 Jul 17. doi: 10.1001/jama.2026.7095.
    PubMed        
    
    

    
    Lancet Oncol

80. VALENZA C, Regan MM, Burstein HJ
    Now or later? Switching therapies in metastatic breast cancer.
    Lancet Oncol. 2026 Jul 13:S1470-2045(26)00332.
    PubMed        
    
    
81. TURNER NC, Mayer EL, Park YH, Janni W, et al
    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 tr
    Lancet Oncol. 2026 Jul 13:S1470-2045(26)00287.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

82. MOREIRA PH, Cardoso ASO, Oliveira R, Santos JGD, et al
    Ensemble machine learning for predicting breast cancer recurrence and mortality using clinical and hemogram data.
    NPJ Breast Cancer. 2026 Jul 11. doi: 10.1038/s41523-026-01005.
    PubMed         Abstract available
    
    

    
    Oncogene

83. MORINAGA T, Hayama S, Nakamura Y, Kawase K, et al
    A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.
    Oncogene. 2026 Jul 10. doi: 10.1038/s41388-026-03894.
    PubMed         Abstract available
    
    

    
    Oncol Rep

84. LI X, Feng L
    Tanshinone IIA in breast cancer: Molecular mechanisms, structural optimization and translational challenges (Review).
    Oncol Rep. 2026;56:150.
    PubMed         Abstract available
    
    

    
    PLoS One

85. NIE S, Liu D, Hu J, Gan Y, et al
    TBX20 promotes doxorubicin resistance in breast cancer cells through enhanced ABCC1 expression and inhibition of mitophagy.
    PLoS One. 2026;21:e0353376.
    PubMed         Abstract available
    
    
86. MAENPAA N, Tiainen L, Martikainen J, Tanner M, et al
    Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.
    PLoS One. 2026;21:e0353941.
    PubMed         Abstract available
    
    
87. RAO NT, Ramana CVV, Karim FK, Aljarbouh A, et al
    ViT-MultiRAGNet: A scalable and reliable retrieval-augmented Vision Transformer framework for memory-guided feature fusion multi-modal mammogram classification.
    PLoS One. 2026;21:e0349865.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

88. GARRIDO A, Price NL, Bernier M, Gomez-Cabrera MC, et al
    Reply to Zhou et al.: Exercise, caloric restriction, and immunotherapy responsiveness in 4T1 breast cancer progression.
    Proc Natl Acad Sci U S A. 2026;123:e2617811123.
    PubMed        
    
    
89. HAN YJ, Olopade OI
    Reply to Chi et al.: Defining BRCA1P1 as a tumor-intrinsic immunoregulatory axis in breast cancer.
    Proc Natl Acad Sci U S A. 2026;123:e2619005123.
    PubMed        
    
    

    
    Radiology

90. TAIB AG, Partridge GJW, Phillips P, Maxwell-Armstrong C, et al
    Automation Bias in Action: Eye Tracking of Humans Reading Screening Mammograms with and without AI Prompts.
    Radiology. 2026;320:e252590.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

91. CHAN J, Knight A, Baker L, Metz G, et al
    Dosimetry and toxicity outcomes of knowledge-based volumetric modulated arc therapy for breast cancer: A retrospective cohort analysis.
    Radiother Oncol. 2026 Jul 17:111704. doi: 10.1016/j.radonc.2026.111704.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum